Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2005 1
2006 1
2007 2
2010 2
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study.
Hentrich MU, Bower M, Daugaard G, Dieing A, Bickel M, Berretta M, Lesmeister F, Jurinovic V, Stoehr A, Heinzelbecker J, Krznaric I, Dieckmann KP, Necchi A, Maroto Rey P, Rockstroh JK, Brito M, Pfister D, Hoffmann C. Hentrich MU, et al. Among authors: maroto rey p. Cancer. 2022 Jan 15;128(2):260-268. doi: 10.1002/cncr.33928. Epub 2021 Sep 30. Cancer. 2022. PMID: 34592009 Free article.
[Rescue chemotherapy in testicular germ cell tumors].
Salazar Soler R, Maroto Rey P, Solà Rocabert C, López López JJ. Salazar Soler R, et al. Among authors: maroto rey p. Arch Esp Urol. 2000 Jul-Aug;53(6):554-64. Arch Esp Urol. 2000. PMID: 11002524 Review. Spanish.
[Treatment decision in advanced testicular germ cell tumors].
Salazar Soler R, Montesinos Muñoz J, Maroto Rey P, Villavicencio Mavrich H. Salazar Soler R, et al. Among authors: maroto rey p. Arch Esp Urol. 2000 Jul-Aug;53(6):522-33. Arch Esp Urol. 2000. PMID: 11002521 Review. Spanish.
[Current treatment in high risk and locally advanced prostate cancer].
Esquena Fernández S, Maroto Rey P, Sancho Pardo G, Palou Redorta J, Villavicencio Mavrich H. Esquena Fernández S, et al. Among authors: maroto rey p. Actas Urol Esp. 2007 May;31(5):445-51. doi: 10.1016/s0210-4806(07)73667-7. Actas Urol Esp. 2007. PMID: 17711162 Review. Spanish.
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
Bellmunt J, Maroto-Rey P, Trigo JM, Carles J, Guillem V, López-Martín JA, Antón-Torres A, Urruticoechea L. Bellmunt J, et al. Among authors: maroto rey p. Clin Transl Oncol. 2010 Jul;12(7):503-8. doi: 10.1007/s12094-010-0544-2. Clin Transl Oncol. 2010. PMID: 20615828 Clinical Trial.
11 results